Skip to main content
SpringerLink
Log in

Pharmacotherapy for Cardiac Diseases

  • Chapter
  • First Online:
Handbook of Cardiac Anatomy, Physiology, and Devices

  • 5162 Accesses

Abstract

Clinical trial design requires inclusion criteria that patients be on optimal medical therapy prior to enrollment or randomization, meaning that they are on medical regimens proven to be safe and effective and considered a standard in clinical practice for the particular disease state being studied. Only then can any clinical or statistical significance be determined between study groups. This chapter outlines optimal medical therapies for hypertension, acute coronary syndrome, myocardial infarction, heart failure, and/or arrhythmias.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Centers for Disease Control and Prevention. (Accessed February 2008, at www.cdc.gov/heartdisease).

  2. American Heart Association. (Accessed February 2008, at www.aha.org).

  3. American Heart Association. Heart disease and stroke statistics: 2008 update. Dallas, TX: American Heart Association, 2008.

    Google Scholar 

  4. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: What it is and what it isn’t. BMJ 1996;312:71–72.

    Article  PubMed  CAS  Google Scholar 

  5. Radford MJ, Heidenreich PA, Bailey SR, et al. ACC/AHA 2007 methodology for the development of clinical data standards. Circulation 2007;115:936–43.

    Article  PubMed  Google Scholar 

  6. Hertz RP, Unger AN, Cornell JA, Saunders E. Racial disparities in hypertension prevalence, awareness, and management. Arch Intern Med 2005;165:2098–104.

    Article  PubMed  Google Scholar 

  7. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. JAMA 2003;289:2560–72.

    Article  PubMed  CAS  Google Scholar 

  8. Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: A scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007;115:2761–88.

    Article  PubMed  Google Scholar 

  9. Furberg CD, Wright JT, Davis BR, et al. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981–97.

    Article  CAS  Google Scholar 

  10. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. Circulation 2000;102:1193–209.

    PubMed  CAS  Google Scholar 

  11. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. Circulation 2004;110:588–636.

    Article  PubMed  Google Scholar 

  12. Antman EM, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowski Z. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 2006;354:1477–88.

    Article  PubMed  CAS  Google Scholar 

  13. King SB III, Smith SC, Hirshfield JW, Jacobs AK, Morrison DA, Williams DO. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. Circulation 2008;117:261–95.

    Article  PubMed  Google Scholar 

  14. Steinhubl SR, Berger PB, Mann JT III, Fry ET, DeLago A, Wilmer C. Early and sustained oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 2002;288:2411–20.

    Article  PubMed  CAS  Google Scholar 

  15. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA 2005 guidelines for the diagnosis and management of chronic heart failure in the adult. Circulation 2005;112:e154–235.

    Article  PubMed  Google Scholar 

  16. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293–302.

    Article  Google Scholar 

  17. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429–35.

    Article  Google Scholar 

  18. MERIT–HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;253:2001–07.

    Google Scholar 

  19. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P. Carvedilol Prospective Randomized Cumulative Survival Study Group: Effect of carvedilol on survival in severe chronic heart failure. New Engl J Med 2001;344:1651–58.

    Article  PubMed  CAS  Google Scholar 

  20. The RALES Investigators. Effectiveness of spironolactone added to angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996;78:902–07.

    Article  Google Scholar 

  21. Granger CB, McMurray JJ, Yusef S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial. Lancet 2003;362:772–76.

    Article  PubMed  CAS  Google Scholar 

  22. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370–75.

    Article  PubMed  CAS  Google Scholar 

  23. Feinberg CD, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation: Analysis and implications. Arch Intern Med 1995;155:469–73.

    Article  PubMed  CAS  Google Scholar 

  24. Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United States, 1989–1998. Circulation 2001;104:2158–63.

    Article  PubMed  CAS  Google Scholar 

  25. Luu M, Stevenson WG, Stevenson LW, Baron K, Walden J. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation 1989;80:1675–80.

    Article  PubMed  CAS  Google Scholar 

  26. Bayes de Luna A, Coumel P, Leclercq JF. Ambulatory sudden cardiac death: Mechanisms of production of fatal arrhythmias on the basis of data from 157 cases. Am Heart J 1989;117:151–60.

    Article  Google Scholar 

  27. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial fibrillation: The Seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest 2004;126:429–56.

    Article  Google Scholar 

  28. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. Circulation 2006;114:e257–354.

    Article  PubMed  Google Scholar 

  29. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. J Am Coll Cardiol 2006;48:e248–346.

    Article  Google Scholar 

  30. Buxton AE, Lee KL, Hafley GE, et al. The Multicenter Unsustained Tachycardia Trial Investigators. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999;341:1882–90.

    Article  PubMed  CAS  Google Scholar 

  31. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter defibrillator for congestive heart failure. N Engl J Med 2005;352:225–37.

    Article  PubMed  CAS  Google Scholar 

  32. The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576–83.

    Article  Google Scholar 

  33. Santini M, Pandozi C, Ricci R. Combining antiarrhythmic drugs and implantable devices therapy: Benefits and outcomes. J Intervent Cardiol Electrophysiol 2000;4:65–89.

    Article  Google Scholar 

  34. Anderson VC, Burcheil K. A prospective study of long-term intrathecal morphine in the management of chronic nonmalignant pain. Neurosurgery 1999;44:289–300.

    Article  PubMed  CAS  Google Scholar 

  35. Albright LA, Gilmartin R, Swift D, Krach LE, Ivanhoe CB, McLaughlin JF. Long-term intrathecal baclofen therapy for severe spasticity of cerebral origin. J Neurosurg 2003;98:291–95.

    Article  PubMed  CAS  Google Scholar 

  36. Waxman S, Moreno R, Rowe KA, Verrier RL. Persistent primary coronary dilation induced by transatrial delivery of nitroglycerin into the pericardial space: A novel approach for local cardiac drug delivery. J Am Coll Cardiol 1999;33:2073–77.

    Article  PubMed  CAS  Google Scholar 

  37. Ujhelyi MR, Hadsall KZ, Eular DE, Mehra R. Intrapericardial therapeutics: A pharmacodynamic and pharmacokinetic comparison between pericardial and intravenous procainamide delivery. J Cardiovasc Electrophysiol 2002;13:605–11.

    Article  PubMed  Google Scholar 

  38. van Brakel TJ, Hermans JJ, Janssen BJ, van Essen H, Botterhuis N, Smits JF. Intrapericardial delivery enhances cardiac effects of sotalol and atenolol. J Cardiovasc Electrophysiol 2004;44:50–56.

    Google Scholar 

  39. Slepian MJ. Polymeric endoluminal gel paving: Therapeutic hydrogel barriers and sustained delivery depots for local arterial wall biomanipulation. Semin Interv Cardiol 1996;1:103–16.

    PubMed  CAS  Google Scholar 

  40. Brieger D, Topal E. Local delivery systems and prevention of stenosis. Cardiovasc Res 1997;35:405–13.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Wisconsin, 777 Highland Avenue, Madison, WI, 58705, USA

    Anna Legreid Dopp

  2. Medtronic, Inc., 135 Highpoint Pass, Fayettville, GA, 30215, USA

    J. Jason Sims

Authors
  1. Anna Legreid Dopp
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Jason Sims
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anna Legreid Dopp .

Editor information

Editors and Affiliations

  1. Dept. Surgery, University of Minnesota, Delaware St. SE., 420, Minneapolis, 55455, U.S.A.

    Paul A. Iaizzo

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Dopp, A.L., Sims, J.J. (2009). Pharmacotherapy for Cardiac Diseases. In: Iaizzo, P. (eds) Handbook of Cardiac Anatomy, Physiology, and Devices. Humana Press. https://doi.org/10.1007/978-1-60327-372-5_24

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-372-5_24

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60327-371-8

  • Online ISBN: 978-1-60327-372-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation